Sign In
Buy TAK
$15.03
-0.150 (-0.99%)
At Close: Jun 03, 2026
Takeda: Pipeline Expanding But Growth Worries Persist
07:35am, Thursday, 16'th Mar 2023
Takeda's late-stage pipeline is impressive with many candidates boasting very strong fundamentals. Technically though, shares are now coming up against significant overhead resistance.
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
11:25am, Thursday, 09'th Mar 2023
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Takeda Pharmaceutical Company Limited (TAK) Q3 2023 Earnings Call Transcript
11:54pm, Thursday, 02'nd Feb 2023
Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q3 2023 Earnings Conference Call February 2, 2023 5:30 AM ET Company Participants Christopher O'Reilly - Head, Investor Relations Christophe Weber - P
7 Sorry Dividend Stocks to Sell in February Before It's Too Late
02:52pm, Monday, 30'th Jan 2023
When it comes to dividend stocks, the consensus is that the higher the yield, the better. High dividend yields can often be an indication that something is wrong.
Takeda inks deal with Hutchmed for up to $1.1 billion
08:31am, Monday, 23'rd Jan 2023
Takeda Pharmaceutical Co. Ltd. TAK, +0.43% 4502, +0.65% said Monday that it will acquire Hutchmed's HCM, +1.46% 13, +1.10% experimental cancer treatment outside mainland China, Hong Kong and Macau, wi
Hutchmed shares jump on US$1.13bn Takeda deal
06:36am, Monday, 23'rd Jan 2023
Shares in Hutchmed (China) Ltd jumped 6.5% after it announced a licensing deal with Takeda Pharmaceutical worth US$1.13bn. With an upfront payment of US$400mln plus milestones, the agreement allows th
100 Best Stocks Of 2022: Oil Stocks And Medicals Shine
06:00pm, Friday, 30'th Dec 2022
Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business
Takeda: Late-Stage Pipeline Catalysts Approaching, But Vyvanse Patent Expiration Looms
02:22pm, Tuesday, 13'th Dec 2022
Entyvio is Takeda's key growth driver, and the management expects it to offset the effect of Vyvanse's patent expiration next year. The company aims to improve margins on its plasma-derived therapies
OSAKA, Japan & CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Takeda ( TSE:4502/NYSE:TAK ) today announced that it will present 15 company-sponsored abstracts at the 64th American Society of Hematology (ASH) A
Takeda: Momentum Building Around Core Offerings, Rate Buy
03:08am, Wednesday, 07'th Dec 2022
Strong top-line growth exhibited in FY22. Building regulatory and clinical momentum around its core offerings, with the bulk of the portfolio up double digits this year.
2 Beaten-Down Dividend Stocks That Haven't Been This Cheap In More Than a Decade
05:11am, Wednesday, 16'th Nov 2022
Is now the time to load up on these high-yielding investments?
Takeda Pharmaceutical Company Limited (TAK) Q2 2022 Earnings Call Transcript
02:44pm, Thursday, 27'th Oct 2022
Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q2 2022 Results Conference Call October 27, 2022 5:30 AM ET Company Participants Ayako Iwamuro - IR Christophe Weber - President and CEO Andrew Plump
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
10:14am, Thursday, 20'th Oct 2022
Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments moving through the pipeline toward FDA approval. The post CRISPR St
3 High-Yielding Dividend Stocks Near Their 52-Week Lows
09:37am, Wednesday, 19'th Oct 2022
These stocks all pay far higher than the S&P 500 average dividend yield of 1.8%.
TAK vs. ZTS: Which Stock Should Value Investors Buy Now?
12:48pm, Wednesday, 21'st Sep 2022
TAK vs. ZTS: Which Stock Is the Better Value Option?
